CN102036676A - 新颖的双重靶向性抗肿瘤轭合物 - Google Patents

新颖的双重靶向性抗肿瘤轭合物 Download PDF

Info

Publication number
CN102036676A
CN102036676A CN200980118231XA CN200980118231A CN102036676A CN 102036676 A CN102036676 A CN 102036676A CN 200980118231X A CN200980118231X A CN 200980118231XA CN 200980118231 A CN200980118231 A CN 200980118231A CN 102036676 A CN102036676 A CN 102036676A
Authority
CN
China
Prior art keywords
formula
cyclic peptide
chemical compound
exist
mentioned above
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200980118231XA
Other languages
English (en)
Chinese (zh)
Inventor
A·达尔波佐
E·埃斯波希托
倪明红
S·彭克
C·皮萨诺
M·卡斯托里纳
L·维西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of CN102036676A publication Critical patent/CN102036676A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN200980118231XA 2008-05-20 2009-05-11 新颖的双重靶向性抗肿瘤轭合物 Pending CN102036676A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08156575 2008-05-20
EP08156575.6 2008-05-20
PCT/EP2009/055653 WO2009141240A1 (en) 2008-05-20 2009-05-11 Novel dual targeting antitumoural conjugates

Publications (1)

Publication Number Publication Date
CN102036676A true CN102036676A (zh) 2011-04-27

Family

ID=39765065

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980118231XA Pending CN102036676A (zh) 2008-05-20 2009-05-11 新颖的双重靶向性抗肿瘤轭合物

Country Status (16)

Country Link
US (1) US20110160147A1 (https=)
EP (1) EP2285396A1 (https=)
JP (1) JP2011523415A (https=)
KR (1) KR20110022594A (https=)
CN (1) CN102036676A (https=)
AR (1) AR071840A1 (https=)
AU (1) AU2009249795A1 (https=)
BR (1) BRPI0911978A2 (https=)
CA (1) CA2724562A1 (https=)
EA (1) EA201071326A1 (https=)
IL (1) IL208920A0 (https=)
MX (1) MX2010012320A (https=)
NZ (1) NZ588948A (https=)
TW (1) TW201004647A (https=)
WO (1) WO2009141240A1 (https=)
ZA (1) ZA201009036B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103333227A (zh) * 2013-06-07 2013-10-02 东南大学 转移肿瘤缺失蛋白小分子环肽抑制剂及其制备方法与应用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7985401B2 (en) 2003-10-31 2011-07-26 The Regents Of The University Of California Peptides whose uptake by cells is controllable
CA2770980A1 (en) 2009-07-15 2011-01-20 Roger Y. Tsien Peptides whose uptake in cells is controllable
CA2816041C (en) * 2010-12-29 2019-01-08 Arrowhead Research Corporation In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
CA2841249C (en) 2011-07-29 2023-09-26 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
US10029017B2 (en) 2013-01-29 2018-07-24 The Regents Of The University Of California Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug
EA031930B1 (ru) 2013-01-30 2019-03-29 Авелас Байосайенсиз, Инк. Молекула селективной доставки для визуализации злокачественной ткани
WO2015095227A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
WO2016008112A1 (en) * 2014-07-16 2016-01-21 Medshine Discovery Inc. Linkers and application towards adc thereof
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
US10125124B2 (en) 2015-03-20 2018-11-13 Massachusetts Institute Of Technology Formation of macromolecules using iterative growth and related compounds
US10596259B2 (en) 2015-05-20 2020-03-24 The Regents Of The University Of California Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof
CN108064246A (zh) 2015-06-15 2018-05-22 基因泰克公司 抗体和免疫结合物
EA202191244A1 (ru) * 2018-11-05 2021-10-11 Байер Фарма Акциенгезельшафт Новые цитостатические конъюгаты с лигандами интегрина

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2370245A1 (en) * 1999-05-14 2000-11-23 Boehringer Ingelheim Pharmaceuticals, Inc. Enzyme-activated anti-tumor prodrug compounds
ITRM20040240A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 7 con antagonisti delle integrine.
US8404650B2 (en) * 2005-10-28 2013-03-26 The Regents Of The University Of Colorado, A Body Corporate Methods of treating cancer with doxazolidine and prodrugs thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103333227A (zh) * 2013-06-07 2013-10-02 东南大学 转移肿瘤缺失蛋白小分子环肽抑制剂及其制备方法与应用
CN103333227B (zh) * 2013-06-07 2015-10-07 东南大学 转移肿瘤缺失蛋白小分子环肽抑制剂及其制备方法与应用

Also Published As

Publication number Publication date
TW201004647A (en) 2010-02-01
EA201071326A1 (ru) 2011-06-30
JP2011523415A (ja) 2011-08-11
MX2010012320A (es) 2010-12-01
NZ588948A (en) 2011-10-28
ZA201009036B (en) 2012-01-25
IL208920A0 (en) 2011-01-31
AU2009249795A1 (en) 2009-11-26
WO2009141240A1 (en) 2009-11-26
KR20110022594A (ko) 2011-03-07
US20110160147A1 (en) 2011-06-30
EP2285396A1 (en) 2011-02-23
BRPI0911978A2 (pt) 2019-09-24
AR071840A1 (es) 2010-07-21
CA2724562A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
CN102036676A (zh) 新颖的双重靶向性抗肿瘤轭合物
CA2660183C (en) Peptides having pharmacological activity for treating disorders associated with altered cell migration, such as cancer
KR20010012809A (ko) 생체막을 통한 수송을 증진시키는 조성물 및 방법
Homma et al. Synthesis and optimization of hyaluronic acid–methotrexate conjugates to maximize benefit in the treatment of osteoarthritis
US20150320876A1 (en) Conformations of divergent peptides with mineral binding affinity
PL207121B1 (pl) Związek kahalalidowy, zastosowanie związku, kompozycja farmaceutyczna oraz sposób wytwarzania związku kahalalidowego
JP2021501201A (ja) ステープルペプチドの細胞内送達のためのポリペプチド接合体
EP2161037A2 (en) Camptothecin-Somatostatin conjugates
AU744425B2 (en) 20(s) camptothecin glycoconjugates
EP1753776B1 (en) Camptothecins conjugated in position 7 to cyclic peptides as cytostatic agents
US11319341B2 (en) Immune-stimulating soluble doxorubicin-conjugated complex
JP2006520741A (ja) 生物医学的及び医学的使用のための新規な両親媒性（ａｍｐｉｐｈｉｌｉｃ）フッ素化炭化水素分子ベクター
JP2001514659A (ja) ドラスタチン−１５誘導体とタキサンとの併用
US20100093612A1 (en) Integrin targeted cyclopeptide ligands, their preparation and use
CN118666946A (zh) 连接子及使用其的偶联药物、抗体偶联药物及其应用
EP1593686B1 (en) Antineoplastic peptides
HK1155363A (en) Novel dual targeting antitumoural conjugates
CN101010103A (zh) 在20位与整联蛋白拮抗剂缀合的喜树碱衍生物
WO2025193573A1 (en) Macrocyclic peptides useful as immunomodulators
CA3208877A1 (en) Cryptophycin compounds and conjugates thereof
JP2007537243A (ja) ２０位にてインテグリンアンタゴニストと接合した７−ｔ−ブトキシイミノメチルカンプトテシン
HK1107005A (en) Camptothecin derivatives conjugated in position 20 with integrin antagonists
HK1259948A1 (en) Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
MXPA99010704A (en) Composition and method for enhancing transport across biological membranes
CZ200132A3 (cs) Podávači systém

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1155363

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110427

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1155363

Country of ref document: HK